Literature DB >> 18026768

[Acute thrombo-embolic elevated ST infarct in a patient with essential thrombocytosis].

C Doesch1, A E May, G Toncar-Pflumm, N Anders, T Geisler, S Kröber, R Kandolf, M Gawaz.   

Abstract

A 48-year-old man presented with acute chest pain and a greatly increased platelet count. Emergency coronary angiographic revealed thrombotic occlusion of the right coronary artery. Coronary angioplasty and stenting were successfully combined with intracoronary abciximab administration. Due to inadequate postinterventional platelet inhibition an intensified dual antiplatelet therapy with acetylsalicylic acid (ASS) and clopidogrel was applied to prevent stent thrombosis. Due to the thrombo-embolic complication and a platelet count over 1 million/microl a cytoreductive treatment with hydroxyurea was initiated.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18026768     DOI： 10.1007/s00108-007-1942-6

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN： 0020-9554            Impact factor:   0.743


  9 in total

1.  Platelet response to clopidogrel is attenuated in diabetic patients undergoing coronary stent implantation.

Authors:  Tobias Geisler; Nicole Anders; Maria Paterok; Harald Langer; Konstantinos Stellos; Stephan Lindemann; Christian Herdeg; Andreas E May; Meinrad Gawaz
Journal:  Diabetes Care       Date:  2007-02       Impact factor: 19.112

2.  Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation.

Authors:  Tobias Geisler; Harald Langer; Magdalena Wydymus; Katrin Göhring; Christine Zürn; Boris Bigalke; Konstantinos Stellos; Andreas E May; Meinrad Gawaz
Journal:  Eur Heart J       Date:  2006-09-27       Impact factor: 29.983

3.  Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.

Authors:  Claire N Harrison; Peter J Campbell; Georgina Buck; Keith Wheatley; Clare L East; David Bareford; Bridget S Wilkins; Jon D van der Walt; John T Reilly; Andrew P Grigg; Paul Revell; Barrie E Woodcock; Anthony R Green
Journal:  N Engl J Med       Date:  2005-07-07       Impact factor: 91.245

Review 4.  Thrombotic complications in essential thrombocythemia (ET): clinical facts and biochemical riddles.

Authors:  Petro E Petrides; Fabian Siegel
Journal:  Blood Cells Mol Dis       Date:  2006-03-24       Impact factor: 3.039

Review 5.  Essential thrombocythemia: scientific advances and current practice.

Authors:  Ayalew Tefferi
Journal:  Curr Opin Hematol       Date:  2006-03       Impact factor: 3.284

Review 6.  Aspirin for the control of platelet activation and prevention of thrombosis in essential thrombocythemia and polycythemia vera: current insights and rationale for future studies.

Authors:  Raffaele Landolfi; Leonardo Di Gennaro; Linda Novarese; Carlo Patrono
Journal:  Semin Thromb Hemost       Date:  2006-04       Impact factor: 4.180

7.  A gain-of-function mutation of JAK2 in myeloproliferative disorders.

Authors:  Robert Kralovics; Francesco Passamonti; Andreas S Buser; Soon-Siong Teo; Ralph Tiedt; Jakob R Passweg; Andre Tichelli; Mario Cazzola; Radek C Skoda
Journal:  N Engl J Med       Date:  2005-04-28       Impact factor: 91.245

8.  Acute coronary disease in essential thrombocythemia and polycythemia vera.

Authors:  C Rossi; M L Randi; P Zerbinati; V Rinaldi; A Girolami
Journal:  J Intern Med       Date:  1998-07       Impact factor: 8.989

9.  Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia.

Authors:  S Cortelazzo; P Viero; G Finazzi; A D'Emilio; F Rodeghiero; T Barbui
Journal:  J Clin Oncol       Date:  1990-03       Impact factor: 44.544
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.